A Phase 3 interventional study of Pemetrexed and Cisplatin in Non-Small Cell Lung Cancer, sponsored by Eli Lilly and Company. Completed at 69 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-12-14.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung — 21 open to participants now, 32 under way, 11 of them phase 3. Pemetrexed · Carcinoma, Non-Small-Cell Lung.
Among the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, this one is the 5th largest by enrollment of the 223 interventional ones that give a count, is one of 14 that started in 2008, is one of 44 in phase 3, and was the 79th registered.
7,624 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →21 of the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Belgium, Brazil and 17 more countries
Ages 18+
Guangzhou Medical University · Sites in China
Ages 18–75
Second Affiliated Hospital of Nanchang University · Sites in China
Ages 18–85
Shanghai Chest Hospital · Sites in China
Ages 18+
Taipei Veterans General Hospital, Taiwan · Sites in Taiwan
Ages 20+
By country, each count listing its studies:
Pemetrexed: first FDA approval 2004 (ALIMTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
227 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 39 · Phase 2 148 · Phase 3 47 · Phase 4 8
First in 2001; this study’s year is marked. 14 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 939 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 64 across the 223 interventional studies. Of the 161 that completed or were terminated, 89 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
76 of 227 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company: 6 open now, 20 under way, 6 of them phase 3. Of 121 finished, 81 (67%) have results posted.
Among the 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company, this one is the 5th largest by enrollment of the 139 interventional ones that give a count, is one of 6 that started in 2008, is one of 25 in phase 3, and was the 65th registered.
Eli Lilly and Company’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
7 of the studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04585490Phase 3Stanford UniversityAdaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC | 2026-12 |
| NCT06417814Phase 3AstraZenecaA Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 2027-01-11 |
| NCT03178552Phase 3Hoffmann-La RocheA Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) | 2027-06-30 |
| NCT05805631Taipei Veterans General Hospital, TaiwanIntrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC | 2026-12-31 |
| NCT06440954Hunan Province Tumor HospitalEfficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases | 2026-12-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Eli Lilly and Company’s 147 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
This study will compare progression-free survival in patients with advanced non-squamous non-small cell lung cancer. Patients who do not progress following 4 cycles of induction treatment with pemetrexed and cisplatin will be randomized 2:1 to receive either maintenance pemetrexed or placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria for the Induction Phase:
Inclusion criteria at Randomization for the Maintenance Phase:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
pemetrexed plus cisplatin followed by pemetrexed plus best supportive care
Drug: Pemetrexed · Drug: Cisplatin · Other: Best Supportive Care
pemetrexed plus cisplatin followed by placebo plus best supportive care
Drug: Pemetrexed · Drug: Cisplatin · Drug: Placebo · Other: Best Supportive Care
Induction therapy: 500 mg/m\^2, intravenous (IV), on Day 1 of each 21-day cycle for 4 cycles
Also known as: Alimta, LY231514
Induction therapy: Cisplatin: 75 mg/m\^2, IV, on Day 1 of each 21-day cycle for 4 cycles
Maintenance therapy: Normal saline (0.9% sodium chloride) administered IV on Day 1 every 21-day cycle until progressive disease or treatment discontinuation
Maintenance therapy: 500 mg/m\^2, IV, on Day 1 of each 21-day cycle until progressive disease or treatment discontinuation.
Also known as: Alimta, LY231514
Best Supportive Care is treatment given with the intent to maximize quality of life. Best Supportive Care excludes any treatment in which the goal is to cure or slow the progression of the study disease. Patients will receive Best Supportive Care as judged by their treating physician. Those therapies considered acceptable include, but are not limited to, palliative radiation to extrathoracic structures, antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, and/or nutritional support (enteral or parenteral).
Investigator-assessed Objective Progression-free Survival (PFS)
Investigator-assessed objective PFS was measured from the date of randomization to the first date of objectively determined progressive disease (PD) or death from any cause. For patients not known to have died as of the data cutoff date and who did not have objective PD, PFS was censored at the date of last objective tumor assessment. PD was determined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. PD = 20% increase in sum of longest diameter of target lesions.
Time frame: Date of randomization to the date of measured PD or date of death from any cause (up to 19.3 months)
Independently-assessed Objective Progression-free Survival (PFS)
To further evaluate the robustness of the PFS analysis, Lilly established an independent review of PFS to assess the potential for investigator bias in the determination of objective PD. PFS was measured from the date of randomization to the first date of objectively determined PD or death. For patients alive as of the data cutoff date and who did not have PD, PFS was censored at the date of the last objective tumor assessment. PD was determined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. PD = 20% increase in sum of longest diameter of target lesions.
Time frame: Date of randomization to first date of measured PD or date of death from any cause (up to 19.3 months)
Overall Survival (OS)
OS is the duration from enrollment to death. For patients who are alive, OS is censored at the last contact.
Time frame: Date of randomization to the date of death from any cause up to 39.5 months
Change From Baseline in the EuroQol Instrument (EQ-5D) Index Score
The EQ-5D is a generic instrument that describes health status in 5 attributes (mobility, self-care, pain/discomfort, anxiety/depression, usual activities) using a three level scale (no problem, some problems, and major problems). These combinations of attributes are converted into a weighted health-state Index Score according to the United Kingdom (UK) population-based algorithm. The possible values for the Index Score range from -0.59 (severe problems in all 5 dimensions) to 1.0 (no problem in any dimension).
Time frame: Baseline randomization through 30-day post-discontinuation visit (up to 19.3 months)
Change From Baseline in EuroQol Instrument (EQ-5D) Visual Analog Scale (VAS)
Patients indicate their present health state through completion of the VAS. Possible scores range from 0 (worst imaginable health state) to 100 (best imaginable health state).
Time frame: Baseline randomization through 30-day post-discontinuation visit (up to 19.3 months)
Percentage of Participants With Hospitalizations Due to Adverse Events or Requiring Transfusion (Resource Utilization)
Time frame: Baseline randomization through 30-day post-discontinuation visit (up to 19.3 months)
Percentage of Participants With a Non-Serious Adverse Event (AE) During Maintenance Phase
A summary of non-serious AEs is located in the Reported Adverse Event Module.
Time frame: Baseline randomization through 30-day post-discontinuation visit (up to 49.7 months)
Percentage of Participants With Serious Adverse Events During Maintenance Phase
A summary of serious adverse events is located in the Reported Adverse Event Module.
Time frame: Baseline randomization through 30-day post-discontinuation visit (up to 49.7 months)
Percentage of Participants With Objective Tumor Response (Response Rate) During Maintenance Phase of Study up to Primary Data Cut-Off
Analysis for combined phases was not performed since response was calculated separately for each phase of study. Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response (CR)=disappearance of all target lesions; Partial Response(PR)is at least a 30% decrease in sum of longest diameter of target lesions; Progressive Disease(PD) is at least a 20% increase in sum of longest diameter of target lesions; Stable Disease(SD)=no change or small changes that do not meet the above criteria for CR, PR, or PD.
Time frame: Baseline to date of measured progressive disease (up to 19.3 months)
Percentage of Participants With Independently-Assessed Objective Tumor Response (Response Rate) During Maintenance Phase Up to Primary Data Cut-Off
Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response (CR)=disappearance of all target lesions; Partial Response (PR) is at least a 30% decrease in sum of longest diameter of target lesions; Progressive Disease (PD) is at least a 20% increase in sum of longest diameter of target lesions; Stable Disease (SD)=no change or small changes that do not meet the above criteria for CR, PR, or PD. Response Rate = (CR+PR)/Participants in Arm\*100. Disease Control Rate=(CR+PR+SD)/Number of Participants in Arm\*100.
Time frame: Date of randomization to date of measured PD (up to 19.3 months)
| Milestone | Induction Pemetrexed + Cisplatin | Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed | Pemetrexed + Cisplatin Followed by Placebo |
|---|---|---|---|
| Started | 939 | 0 | 0 |
| Completed | 540 | 0 | 0 |
| Not completed | 399 | 0 | 0 |
| Withdrew: Adverse event | 64 | 0 | 0 |
| Withdrew: Death due to study disease | 24 | 0 | 0 |
| Withdrew: Death due to adverse event | 19 | 0 | 0 |
| Withdrew: Death due to toxicity | 11 | 0 | 0 |
| Withdrew: Death due to procedure | 1 | 0 | 0 |
| Withdrew: Investigator decision | 7 | 0 | 0 |
| Withdrew: Protocol entry criteria not met | 9 | 0 | 0 |
| Withdrew: Lost to follow-up | 6 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 0 |
| Withdrew: Progressive disease | 220 | 0 | 0 |
| Withdrew: Withdrawal by subject | 37 | 0 | 0 |
| Milestone | Induction Pemetrexed + Cisplatin | Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed | Pemetrexed + Cisplatin Followed by Placebo |
|---|---|---|---|
| Started | 0 | 359 | 180 |
| Completed | 0 | 0 | 0 |
| Not completed | 0 | 359 | 180 |
| Withdrew: Adverse event | 0 | 65 | 12 |
| Withdrew: Death due to study disease | 0 | 3 | 1 |
| Withdrew: Death due to adverse event | 0 | 4 | 1 |
| Withdrew: Death due to toxicity | 0 | 1 | 2 |
| Withdrew: Investigator decision | 0 | 4 | 2 |
| Withdrew: Protocol entry criteria not met | 0 | 2 | 0 |
| Withdrew: Lost to follow-up | 0 | 2 | 0 |
| Withdrew: Progressive disease | 0 | 253 | 152 |
| Withdrew: Withdrawal by subject | 0 | 21 | 8 |
| Withdrew: Sponsor decision | 0 | 0 | 2 |
| Withdrew: Participants on-going at data cut-off | 0 | 4 | 0 |
Investigator-assessed objective PFS was measured from the date of randomization to the first date of objectively determined progressive disease (PD) or death from any cause. For patients not known to have died as of the data cutoff date and who did not have objective PD, PFS was censored at the date of last objective tumor assessment. PD was determined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. PD = 20% increase in sum of longest diameter of target lesions.
| months | Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed | Pemetrexed + Cisplatin Followed by Placebo |
|---|---|---|
| Investigator-assessed Objective Progression-free Survival (PFS) | 4.11 (3.15 to 4.57) | 2.83 (2.60 to 3.12) |
To further evaluate the robustness of the PFS analysis, Lilly established an independent review of PFS to assess the potential for investigator bias in the determination of objective PD. PFS was measured from the date of randomization to the first date of objectively determined PD or death. For patients alive as of the data cutoff date and who did not have PD, PFS was censored at the date of the last objective tumor assessment. PD was determined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. PD = 20% increase in sum of longest diameter of target lesions.
| months | Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed | Pemetrexed + Cisplatin Followed by Placebo |
|---|---|---|
| Independently-assessed Objective Progression-free Survival (PFS) | 3.94 (2.96 to 4.24) | 2.60 (2.23 to 2.92) |
OS is the duration from enrollment to death. For patients who are alive, OS is censored at the last contact.
| months | Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed | Pemetrexed + Cisplatin Followed by Placebo |
|---|---|---|
| Overall Survival (OS) | 13.86 (12.75 to 16.03) | 11.01 (9.95 to 12.52) |
The EQ-5D is a generic instrument that describes health status in 5 attributes (mobility, self-care, pain/discomfort, anxiety/depression, usual activities) using a three level scale (no problem, some problems, and major problems). These combinations of attributes are converted into a weighted health-state Index Score according to the United Kingdom (UK) population-based algorithm. The possible values for the Index Score range from -0.59 (severe problems in all 5 dimensions) to 1.0 (no problem in any dimension).
| units on a scale | Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed | Pemetrexed + Cisplatin Followed by Placebo |
|---|---|---|
| Baseline | 0.77 ± 0.21 | 0.79 ± 0.18 |
| Cycle 1 Day 1 | 0.01 ± 0.15 | -0.01 ± 0.17 |
| Cycle 2 Day 1 | 0.0 ± 0.19 | 0.01 ± 0.17 |
| Cycle 3 Day 1 | 0.0 ± 0.15 | 0.03 ± 0.17 |
| Cycle 4 Day 1 | -0.01 ± 0.15 | 0.02 ± 0.18 |
| Cycle 5 Day 1 | 0.01 ± 0.16 | 0.01 ± 0.22 |
| Cycle 6 Day 1 | -0.02 ± 0.18 | 0.04 ± 0.14 |
| Cycle 7 Day 1 | 0.01 ± 0.20 | 0.01 ± 0.13 |
| Cycle 8 Day 1 | 0.01 ± 0.18 | 0.05 ± 0.15 |
| Cycle 9 Day 1 | -0.03 ± 0.20 | 0.06 ± 0.18 |
| Cycle 10 Day 1 | 0.0 ± 0.16 | 0.08 ± 0.15 |
| Cycle 11 Day 1 | -0.02 ± 0.19 | 0.04 ± 0.17 |
| Cycle 12 Day 1 | -0.06 ± 0.27 | 0.06 ± 0.16 |
| Cycle 13 Day 1 | -0.01 ± 0.27 | 0.0 ± 0.0 |
| Cycle 14 Day 1 | 0.03 ± 0.26 | 0.03 ± 0.05 |
| Cycle 15 Day 1 | -0.07 ± 0.34 | 0.01 ± 0.02 |
| Cycle 16 Day 1 | -0.01 ± 0.36 | 0.0 ± 0.0 |
| Cycle 17 Day 1 | 0.32 ± 0.43 | — |
| Cycle 18 Day 1 | 0.45 ± 0.52 | — |
| 30 Day Post-Study Visit | -0.13 ± 0.27 | -0.09 ± 0.26 |
Patients indicate their present health state through completion of the VAS. Possible scores range from 0 (worst imaginable health state) to 100 (best imaginable health state).
| units on a scale | Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed | Pemetrexed + Cisplatin Followed by Placebo |
|---|---|---|
| Baseline | 71.1 ± 16.6 | 71.0 ± 15.8 |
| Cycle 1 Day 1 | 1.65 ± 9.86 | 1.42 ± 10.2 |
| Cycle 2 Day 1 | 1.24 ± 11.2 | 3.15 ± 13.0 |
| Cycle 3 Day 1 | 1.82 ± 10.9 | 4.90 ± 16.9 |
| Cycle 4 Day 1 | 0.69 ± 13.1 | 6.15 ± 16.4 |
| Cycle 5 Day 1 | 1.55 ± 12.4 | 5.99 ± 13.1 |
| Cycle 6 Day 1 | 3.01 ± 12.5 | 5.76 ± 12.9 |
| Cycle 7 Day 1 | 2.7 ± 14.5 | 3.98 ± 10.9 |
| Cycle 8 Day 1 | 4.12 ± 14.1 | 7.58 ± 14.8 |
| Cycle 9 Day 1 | 4.19 ± 14.2 | 7.61 ± 16.7 |
| Cycle 10 Day 1 | 5.14 ± 15.1 | 6.23 ± 18.7 |
| Cycle 11 Day 1 | 2.58 ± 14.7 | 0.94 ± 15.4 |
| Cycle 12 Day 1 | 2.11 ± 16.0 | 4.63 ± 13.1 |
| Cycle 13 Day 1 | 6.29 ± 16.4 | 10.0 ± 3.27 |
| Cycle 14 Day 1 | 3.64 ± 18.4 | 14.0 ± 4.55 |
| Cycle 15 Day 1 | 8.40 ± 12.9 | 12.0 ± 3.46 |
| Cycle 16 Day 1 | 5.83 ± 9.99 | 15.0 ± 0.0 |
| Cycle 17 Day 1 | 15.7 ± 21.1 | — |
| Cycle 18 Day 1 | 5.0 ± 14.1 | — |
| 30 days post-study | -4.77 ± 17.3 | -3.92 ± 16.7 |
| percentage of participants | Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed | Pemetrexed + Cisplatin Followed by Placebo |
|---|---|---|
| Hospitalization due to Drug-related Adverse Event | 8.4 | 3.3 |
| Transfusions Packed Red Blood Cells | 12.3 | 4.4 |
| Transfusions Whole Blood | 1.4 | 0.6 |
| Transfusions Platelets | 1.4 | 0.6 |
| Transfusions Fresh Frozen Plasma | 0 | 0.6 |
A summary of non-serious AEs is located in the Reported Adverse Event Module.
| percentage of participants | Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed | Pemetrexed Plus Cisplatin Followed by Placebo |
|---|---|---|
| Non-Serious AEs at 2% Threshold: up to 19.3 Month | 59.9 | 50.6 |
| Non-Serious AEs at 5% Threshold: up to 49.7 Months | 75.5 | 62.2 |
A summary of serious adverse events is located in the Reported Adverse Event Module.
| percentage of participants | Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed | Pemetrexed Plus Cisplatin Followed by Placebo |
|---|---|---|
| Serious Adverse Events: up to 19.3 Months | 18.9 | 12.2 |
| Serious Adverse Events: up to 49.7 Months | 26.2 | 20.0 |
Analysis for combined phases was not performed since response was calculated separately for each phase of study. Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response (CR)=disappearance of all target lesions; Partial Response(PR)is at least a 30% decrease in sum of longest diameter of target lesions; Progressive Disease(PD) is at least a 20% increase in sum of longest diameter of target lesions; Stable Disease(SD)=no change or small changes that do not meet the above criteria for CR, PR, or PD.
| percentage of participants | Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed | Pemetrexed + Cisplatin Followed by Placebo |
|---|---|---|
| Percentage of Participants With Objective Tumor Response (Response Rate) During Maintenance Phase of Study up to Primary Data Cut-Off | 46.2 | 42.2 |
Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response (CR)=disappearance of all target lesions; Partial Response (PR) is at least a 30% decrease in sum of longest diameter of target lesions; Progressive Disease (PD) is at least a 20% increase in sum of longest diameter of target lesions; Stable Disease (SD)=no change or small changes that do not meet the above criteria for CR, PR, or PD. Response Rate = (CR+PR)/Participants in Arm\*100. Disease Control Rate=(CR+PR+SD)/Number of Participants in Arm\*100.
| percentage of participants | Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed | Pemetrexed + Cisplatin Followed by Placebo |
|---|---|---|
| Response Rate | 46.2 (41.0 to 51.6) | 42.2 (34.9 to 49.8) |
| Disease Control Rate | 98.1 (96.0 to 99.2) | 94.4 (90.0 to 97.3) |
Collected over From start of study up to approximately 108 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Induction Pemetrexed + Cisplatin | — | 257/939 (27.4%) | 759/939 (80.8%) |
| Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed | — | 94/359 (26.2%) | 287/359 (79.9%) |
| Pemetrexed + Cisplatin Followed by Placebo | — | 36/180 (20%) | 117/180 (65%) |
| Event | Induction Pemetrexed + Cisplatin | Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed | Pemetrexed + Cisplatin Followed by Placebo |
|---|---|---|---|
| VomitingGastrointestinal disorders | 29/939 | 3/359 | 1/180 |
| AnaemiaBlood and lymphatic system disorders | 13/939 | 11/359 | 1/180 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 28/939 | 3/359 | 3/180 |
| NauseaGastrointestinal disorders | 24/939 | 2/359 | 1/180 |
| Back painMusculoskeletal and connective tissue disorders | 4/939 | 1/359 | 4/180 |
| PneumoniaInfections and infestations | 17/939 | 5/359 | 3/180 |
| Febrile neutropeniaBlood and lymphatic system disorders | 12/939 | 6/359 | 0/180 |
| NeutropeniaBlood and lymphatic system disorders | 8/939 | 6/359 | 0/180 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 15/939 | 6/359 | 3/180 |
| ThrombocytopeniaBlood and lymphatic system disorders | 7/939 | 5/359 | 0/180 |
| Event | Induction Pemetrexed + Cisplatin | Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed | Pemetrexed + Cisplatin Followed by Placebo |
|---|---|---|---|
| NauseaGastrointestinal disorders | 362/939 | 69/359 | 8/180 |
| VomitingGastrointestinal disorders | 210/939 | 42/359 | 9/180 |
| AnaemiaBlood and lymphatic system disorders | 152/939 | 76/359 | 5/180 |
| FatigueGeneral disorders | 181/939 | 55/359 | 16/180 |
| NeutropeniaBlood and lymphatic system disorders | 158/939 | 38/359 | 3/180 |
| AstheniaGeneral disorders | 141/939 | 51/359 | 8/180 |
| ConstipationGastrointestinal disorders | 131/939 | 23/359 | 14/180 |
| Decreased appetiteMetabolism and nutrition disorders | 119/939 | 32/359 | 6/180 |
| Oedema peripheralGeneral disorders | 42/939 | 45/359 | 5/180 |
| DiarrhoeaGastrointestinal disorders | 114/939 | 28/359 | 7/180 |
| Age, Continuous(years) | Induction Pemetrexed + Cisplatin |
|---|---|
| Median | 61.3 (24.4 to 83.0) |
| Sex: Female, Male(Participants) | Induction Pemetrexed + Cisplatin |
|---|---|
| Female | 362 |
| Male | 577 |
| Race/Ethnicity, Customized(participants) | Induction Pemetrexed + Cisplatin |
|---|---|
| Asian | 59 |
| African | 7 |
| Multiple | 2 |
| Caucasian | 871 |
| Region of Enrollment(participants) | Induction Pemetrexed + Cisplatin |
|---|---|
| Portugal | 38 |
| Greece | 34 |
| Finland | 18 |
| Spain | 65 |
| Turkey | 33 |
| United Kingdom | 71 |
| Italy | 175 |
| India | 54 |
| France | 106 |
| Poland | 34 |
| Belgium | 53 |
| Romania | 55 |
| Australia | 26 |
| Netherlands | 48 |
| Germany | 126 |
| Canada | 3 |
| Smoking Status(participants) | Induction Pemetrexed + Cisplatin |
|---|---|
| Ever Smoker | 757 |
| Never Smoker | 175 |
| Unknown | 7 |
The record gives a start of Nov 2008, a primary completion of Jun 2010 and a completion of Nov 2017. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2011, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pemetrexed · Cisplatin
Carcinoma, Non-Small-Cell Lung →